Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

Core Viewpoint - Helix BioPharma Corp. is extending its Annual General and Special Meeting to March 26, 2025, to secure shareholder approval for proposed asset acquisitions and financing arrangements [1][2]. Group 1: Meeting Details - The Annual General and Special Meeting has been rescheduled to March 26, 2025, to allow more time for shareholder approval regarding asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG [1]. - The Ontario Superior Court of Justice approved the application to hold the Meeting by the new date on February 26, 2025 [2]. - Meeting materials, including the Notice of Meeting and Voting Instruction Form, were mailed to shareholders and posted on SEDAR+ on February 24, 2025 [3]. Group 2: Shareholder Participation - Shareholders of record as of January 31, 2025, are eligible to vote at the Meeting and are encouraged to vote in advance [4]. - Proxies must be received by 10 a.m. (EST) on March 24, 2025, to be counted [4]. Group 3: Company Overview - Helix BioPharma Corp. is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes a proprietary technology platform targeting CEACAM6-expressing solid tumors [6]. - The lead candidate, Tumour Defence BreakerTM L-DOS47, is an antibody-enzyme conjugate that aims to enhance anti-cancer immunity and has completed Phase Ib studies in non-small cell lung cancer [6][7].